skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

Authors:
 [1];  [1];  [1];  [1];  [1];  [1]
  1. IRCCS Neuromed, Pozzilli Italy
Publication Date:
Sponsoring Org.:
USDOE Office of Electricity Delivery and Energy Reliability (OE), Power Systems Engineering Research and Development (R&D) (OE-10)
OSTI Identifier:
1224661
Alternate Identifier(s):
OSTI ID: 1345705
Resource Type:
Published Article
Journal Name:
Journal of Cellular and Molecular Medicine
Additional Journal Information:
Journal Name: Journal of Cellular and Molecular Medicine Journal Volume: 19 Journal Issue: 11; Journal ID: ISSN 1582-1838
Publisher:
Wiley-Blackwell
Country of Publication:
Country unknown/Code not available
Language:
English

Citation Formats

Squitieri, Ferdinando, Di Pardo, Alba, Favellato, Mariagrazia, Amico, Enrico, Maglione, Vittorio, and Frati, Luigi. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. Country unknown/Code not available: N. p., 2015. Web. doi:10.1111/jcmm.12604.
Squitieri, Ferdinando, Di Pardo, Alba, Favellato, Mariagrazia, Amico, Enrico, Maglione, Vittorio, & Frati, Luigi. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. Country unknown/Code not available. doi:10.1111/jcmm.12604.
Squitieri, Ferdinando, Di Pardo, Alba, Favellato, Mariagrazia, Amico, Enrico, Maglione, Vittorio, and Frati, Luigi. Mon . "Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model". Country unknown/Code not available. doi:10.1111/jcmm.12604.
@article{osti_1224661,
title = {Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model},
author = {Squitieri, Ferdinando and Di Pardo, Alba and Favellato, Mariagrazia and Amico, Enrico and Maglione, Vittorio and Frati, Luigi},
abstractNote = {},
doi = {10.1111/jcmm.12604},
journal = {Journal of Cellular and Molecular Medicine},
number = 11,
volume = 19,
place = {Country unknown/Code not available},
year = {2015},
month = {6}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
DOI: 10.1111/jcmm.12604

Citation Metrics:
Cited by: 10 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Differences in agonist/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208-912
journal, November 2007

  • Tadori, Yoshihiro; Kitagawa, Hisashi; Forbes, Robert A.
  • European Journal of Pharmacology, Vol. 574, Issue 2-3
  • DOI: 10.1016/j.ejphar.2007.07.031

Neurochemical Alterations in Huntington'S Chorea: a Study of Post-Mortem Brain Tissue
journal, January 1980


FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease
journal, December 2013

  • Di Pardo, Alba; Amico, Enrico; Favellato, Mariagrazia
  • Human Molecular Genetics, Vol. 23, Issue 9
  • DOI: 10.1093/hmg/ddt615

Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice
journal, February 2012

  • Di Pardo, A.; Maglione, V.; Alpaugh, M.
  • Proceedings of the National Academy of Sciences, Vol. 109, Issue 9
  • DOI: 10.1073/pnas.1114502109

Changes in brainstem serotonergic and dopaminergic cell populations in experimental and clinical Huntington’s disease
journal, May 2013


Altered Dopamine and Serotonin Metabolism in Motorically Asymptomatic R6/2 Mice
journal, March 2011


Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice
journal, April 2012

  • Crook, Z. R.; Housman, D. E.
  • Proceedings of the National Academy of Sciences, Vol. 109, Issue 19
  • DOI: 10.1073/pnas.1204542109

Dopamine and Glutamate in Huntington's Disease: A Balancing Act: Dopamine-Glutamate Balance in Huntington's Disease
journal, May 2010


Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival
journal, November 2007


In vivo pharmacology of the dopaminergic stabilizer pridopidine
journal, October 2010

  • Ponten, Henrik; Kullingsjö, Johan; Lagerkvist, Sören
  • European Journal of Pharmacology, Vol. 644, Issue 1-3
  • DOI: 10.1016/j.ejphar.2010.07.023

The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea
journal, November 2006


Rat liver and kidney contain high densities of σ1 and σ2 receptors: characterization by ligand binding and photoaffinity labeling
journal, June 1994

  • Hellewell, Susan B.; Bruce, Ashley; Feinstein, Glen
  • European Journal of Pharmacology: Molecular Pharmacology, Vol. 268, Issue 1
  • DOI: 10.1016/0922-4106(94)90115-5

The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition
journal, July 2004

  • Nilsson, Marie; Carlsson, Arvid; Markinhuhta, Katarina Rydén
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 28, Issue 4
  • DOI: 10.1016/j.pnpbp.2004.05.004

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
journal, December 2011

  • de Yebenes, Justo Garcia; Landwehrmeyer, Bernhard; Squitieri, Ferdinando
  • The Lancet Neurology, Vol. 10, Issue 12
  • DOI: 10.1016/S1474-4422(11)70233-2

The Physiology, Signaling, and Pharmacology of Dopamine Receptors
journal, February 2011

  • Beaulieu, Jean-Martin; Gainetdinov, Raul R.
  • Pharmacological Reviews, Vol. 63, Issue 1
  • DOI: 10.1124/pr.110.002642

Huntingtin Aggregate-Associated Axonal Degeneration is an Early Pathological Event in Huntington's Disease Mice
journal, November 2001


The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the σ-1 receptor
journal, February 2012

  • Sahlholm, K.; Århem, P.; Fuxe, K.
  • Molecular Psychiatry, Vol. 18, Issue 1
  • DOI: 10.1038/mp.2012.3

Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders
journal, February 2011


Is DARPP-32 a potential therapeutic target?
journal, November 2007

  • Reis, Helton J.; Rosa, Daniela VF; Guimarães, Melissa M.
  • Expert Opinion on Therapeutic Targets, Vol. 11, Issue 12
  • DOI: 10.1517/14728222.11.12.1649

Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease
journal, January 2010


Mini Review
journal, January 2004


Chemical Pathology of Huntington's Disease
journal, April 1980


Impaired Ganglioside Metabolism in Huntington's Disease and Neuroprotective Role of GM1
journal, March 2010


Inotropic action of σ receptor ligands in isolated cardiac myocytes from adult rats
journal, November 1995


Role of brain-derived neurotrophic factor in Huntington's disease
journal, April 2007


One-year safety and tolerability profile of pridopidine in patients with Huntington disease
journal, February 2013


Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders
journal, January 2003

  • Sánchez, Ivelisse; Mahlke, Christian; Yuan, Junying
  • Nature, Vol. 421, Issue 6921
  • DOI: 10.1038/nature01301